Bexarotene plus radiation for mycosis fungoides skin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and have biopsy-confirmed mycosis fungoides (a cutaneous T-cell lymphoma)
- Have stage IB or higher mycosis fungoides (or have Sézary syndrome along with it is allowed)
- Have a mSWAT skin score of at least 10
- Your usual itching medicines can stay the same if already stable, but you cannot start new itching medicines after enrolling
- Be able to consent and have a good enough day-to-day function (ECOG performance status 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This Phase 3 study tests a low-dose skin radiation treatment (electron beam) to help eradicate the harmful cancer cells in early-stage mycosis fungoides. It may be an option if you have stage IB or IIA disease and can safely undergo the required light/radiation preparation steps.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
This early-phase study tests a spray solution (APR-TD011®) for people with early-stage mycosis fungoides and looks at how the bacteria on the skin change before and after treatment. It may help researchers understand whether the spray improves the skin environment that can affect this lymphoma.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.